secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001193125-24-180750
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD
-----------------------------------------------------------------------------

- FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.
- This is the third FDA approval for VOQUEZNA; also approved for Erosive GERD and H. pylori eradication.
- Approximately 45 million US adults have Non-Erosive GERD; about 15 million treated with prescription medicine annually.
- Non-Erosive GERD is the largest GERD category, characterized by reflux symptoms without esophageal erosions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524180750/0001193125-24-180750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524180750/d812423d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-180750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer